Suppressor cells in antigenic competition in contact allergy in mice. 1978

K Nakano, and Y Nakano

The effects of cyclophosphamide (CY) thymectomy and splenectomy on the antigenic competition in contact hypersensitivity between dinitrofluorobenzene (DNFB) and picryl chloride (PCI) was investigated. Contact sensitivity of PCI was suppressed by a prior painting of DNFB. When these two sensitizers were painted 7 days apart and CY was injected 3 days after the painting of DNFB, the antigenic competition did not occur. On the other hand, when CY was injected 3 days before painting of DNFB, the antigenic competition was partially abolished. The antigenic competition was seen in mice 2 weeks after adult thymectomy and in splenectomized mice. However, antigenic competition did not occur in mice 6 weeks after thymectomy. These results suggest that some thymus-derived cells may be involved in the antigenic competition in contact sensitivity.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008297 Male Males
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003877 Dermatitis, Contact A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms. Contact Dermatitis,Dermatitis Venenata,Eczema, Contact,Hypersensitivity, Contact,Sensitivity, Contact,Contact Dermatitides,Contact Eczema,Contact Hypersensitivities,Contact Hypersensitivity,Contact Sensitivities,Contact Sensitivity,Dermatitides, Contact,Hypersensitivities, Contact,Sensitivities, Contact
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D000937 Antigen-Antibody Reactions The processes triggered by interactions of ANTIBODIES with their ANTIGENS. Antigen Antibody Reactions,Antigen-Antibody Reaction,Reaction, Antigen-Antibody,Reactions, Antigen-Antibody
D013156 Splenectomy Surgical procedure involving either partial or entire removal of the spleen. Splenectomies

Related Publications

K Nakano, and Y Nakano
January 1984, Annales de dermatologie et de venereologie,
K Nakano, and Y Nakano
June 1990, Journal of clinical & laboratory immunology,
K Nakano, and Y Nakano
May 1982, Journal of the American Academy of Dermatology,
K Nakano, and Y Nakano
June 1971, Experientia,
K Nakano, and Y Nakano
December 1972, European journal of immunology,
K Nakano, and Y Nakano
January 1985, International archives of allergy and applied immunology,
K Nakano, and Y Nakano
January 1973, Current topics in microbiology and immunology,
K Nakano, and Y Nakano
January 1975, Progress in allergy,
Copied contents to your clipboard!